Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2549-2557
Open Access | Times Cited: 41
Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen
Szu‐Ting Yang, Wen-Hsun Chang, Fang-Wei Chou, et al.
Taiwanese Journal of Obstetrics and Gynecology (2024) Vol. 63, Iss. 1, pp. 10-16
Open Access | Times Cited: 24
Prognostic significance of pathological response and lymph node status in neoadjuvant immunotherapy for potentially resectable non-small cell lung cancer
Yuan Xu, Dongjie Ma, Yingzhi Qin, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 1
Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis
Lei‐Ming Cao, Yi-Fu Yu, Zi‐Zhan Li, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
Xufeng Guo, Chunji Chen, Jinbo Zhao, et al.
JAMA Surgery (2025)
Closed Access | Times Cited: 1
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Christopher J.M. Williams, Allyson Peddle, Pashtoon Murtaza Kasi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 12, pp. 839-851
Closed Access | Times Cited: 8
Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial
Chao Sun, Xu Wang, Yinghui Xu, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102422-102422
Open Access | Times Cited: 6
Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA/IIIB NSCLC: a retrospective study
Yuchen Wang, Xiaobo Ma, Kewei Ma, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial
Haichao Huang, Tao Wang, Xing Li, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Prognostic Implications of Lymph Node Status in Non-Small Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study
Ran Ma, Haitang Yang, Yong Ge, et al.
Clinical Lung Cancer (2025)
Closed Access
Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma in real-world practice: an analysis of the clinical outcomes and long-term survival, and the feasibility of using major pathological response as a surrogate endpoint
Jia-Cong Liu, Ziheng Wu, Shihong Zhou, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Correlation between PD-L1 expression and FDG-PET/CT visual assessments in non-small cell lung cancer resected specimens
Miki Nishimori, Hitomi Iwasa, Kana Miyatake, et al.
Nuclear Medicine Communications (2025)
Closed Access
Molecular imaging research on 18F-FDG PET/CT and biomarker analysis predicts the pathological response to neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIB NSCLC.
Kaiyue Wang, Xiaohan Wang, Xue Meng, et al.
Research Square (Research Square) (2025)
Closed Access
Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma
Jia-Cong Liu, Linhai Zhu, Muhu Tang, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review
Kyoichi Kaira, Yoshinobu Ichiki, Hisao Imai, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 5, pp. 1137-1149
Open Access | Times Cited: 2
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy
Lei Ji, Xi Chen, Xiaoyan Qian, et al.
The Breast (2024) Vol. 78, pp. 103792-103792
Open Access | Times Cited: 1
Neoadjuvant chemoimmunotherapy for laryngeal preservation in locally advanced hypopharyngeal cancer
Yafeng Pan, Haopu Li, Minhui Zhu, et al.
International Immunopharmacology (2024) Vol. 142, pp. 113197-113197
Closed Access | Times Cited: 1
Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
Yunchang Meng, Qingfeng Zhang, Ranpu Wu, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Major Pathologic Response as a Prognostic Surrogate in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemotherapy/Chemoimmunotherapy: a Multi-center Cohort Study
Zhi-Nuan Hong, Shuhan Xie, Hui Xu, et al.
European Journal of Surgical Oncology (2024) Vol. 51, Iss. 2, pp. 109500-109500
Open Access | Times Cited: 1
Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
Ye Wang, Yingqiu Song, Runze Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study
Dan Han, Hao Li, Xin Zheng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study
Mingming Hu, Xiaomi Li, Haifeng Lin, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 4, pp. 2275-2287
Open Access
The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis
Yanmeng Wu, Lin Hu, Shuling Zhang, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access
Pulmonary function test-related prognostic models in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy
Min Zhang, Liang Zhu, Sibei Liang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis
Bo Li, Yujia Gu, Weixing Zhao, et al.
Clinical & Translational Oncology (2024)
Closed Access
Page 1 - Next Page

Scroll to top